Literature DB >> 11313395

Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.

D J Nelson1, S Mukherjee, C Bundell, S Fisher, D van Hagen, B Robinson.   

Abstract

To determine whether APC function or "arming" of CTL for lytic function are the points at which Ags from a nonimmunogenic tumor fail to induce an effective immune response, we established a murine tumor model that expressed intracellular OVA and selected a clone (cOVA-9) that remained susceptible to lysis by specific CD8(+) T cells throughout tumor growth. Viable cOVA-9 tumor cells grew in normal mice at a rate similar to the parental tumor, and vaccination with irradiated cOVA-9 cells did not induce protection against itself or the parental line, confirming its nonimmunogenic status. In vivo evaluation during tumor growth demonstrated persisting tumor Ag cross-presentation accompanied by the generation of potent, specific CTL which were detectable when tumors were barely palpable. Despite the presence of highly active CTL in the tumor-draining lymph nodes, there was no apparent lysis of tumor-associated APC. These data show that tumor-draining APC are not dysfunctional with regard to two crucial processes, in vivo tumor Ag cross-presentation and specific CTL arming, and that failure to prevent tumor growth is not in the induction phase, but in the effector phase and occurs within the tumor itself before the tumor matrix is established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313395     DOI: 10.4049/jimmunol.166.9.5557

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

3.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Authors:  David C Jackson; Yuk Fai Lau; Thuy Le; Andreas Suhrbier; Georgia Deliyannis; Christina Cheers; Corey Smith; Weiguang Zeng; Lorena E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

Review 4.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

5.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

6.  CD4 cells can be more efficient at tumor rejection than CD8 cells.

Authors:  Ainhoa Perez-Diez; Nathalie T Joncker; Kyungho Choi; William F N Chan; Colin C Anderson; Olivier Lantz; Polly Matzinger
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

7.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.

Authors:  Katherine A Murphy; Jami R Erickson; Charles S Johnson; Charles E Seiler; Jessica Bedi; Peisheng Hu; G Elizabeth Pluhar; Alan L Epstein; John R Ohlfest
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

9.  Turning the tumor microenvironment into a self vaccine site.

Authors:  Delia J Nelson
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

Review 10.  Contribution of the immune system to the chemotherapeutic response.

Authors:  Alison M McDonnell; Anna K Nowak; Richard A Lake
Journal:  Semin Immunopathol       Date:  2011-01-28       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.